Parathyroid Gland Function in Primary Aldosteronism

Abstract

Primary aldosteronism (PA) is the most frequent cause of secondary arterial hypertension. Beyond its effects on intravascular volume and blood pressure, PA causes metabolic alterations and a higher cardiovascular morbidity, which is reduced by PA-directed therapy. Experimental studies demonstrated that mineralocorticoid excess may also influence mineral homeostasis. A role in cardiovascular disease has also been attributed to parathyroid hormone (PTH). Increasing evidence supports a bidirectional interaction between aldosterone and PTH.

Primary hyperparathyroidism is associated with arterial hypertension and an increased cardiovascular morbidity and mortality, which might be associated to higher aldosterone values; parathyreoidectomy results in lowered aldosterone and blood pressure levels. PA leads to secondary hyperparathyroidism, which is reversible by PA-directed therapy. A lower bone mineral density and a higher fracture rate were also shown to be reversible by PA-directed therapy. There is a suspicion of a bidirectional interaction between aldosterone and PTH, which might lead to a higher cardiovascular risk. There are more and more reports about coincident PA and primary hyperparathyroidism. From a pathophysiologic point of view this constellation is best characterized as tertiary hyperparathyroidism. Future aspects should further clarify the extent of these endocrine interactions and analyze the influence of this interplay on cardiovascular morbidity and mortality and bone health.

Key words

primary aldosteronism - aldosterone - hyperparathyroidism - parathyroid hormone

Publikationsverlauf

Eingereicht: 15. August 2015

Angenommen: 06. November 2015

Artikel online veröffentlicht:
14. Dezember 2015

• References

• 1 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
• 2 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
• 3 Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension 2012; 60: 618-624
• 4 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
• 5 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
• 6 Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004; 287: H2023-H2026
• 7 Runyan AL, Chhokar VS, Sun Y, Bhattacharya SK, Runyan JW, Weber KT. Bone loss in rats with aldosteronism. Am J Med Sci 2005; 330: 1-7
• 8 Carbone LD, Cross JD, Raza SH, Bush AJ, Sepanski RJ, Dhawan S, Khan BQ, Gupta M, Ahmad K, Khouzam RN, Dishmon DA, Nesheiwat JP, Hajjar MA, Chishti WA, Nasser W, Khan M, Womack CR, Cho T, Haskin AR, Weber KT. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008; 52: 135-138
• 9 van Ballegooijen AJ, Reinders I, Visser M, Dekker JM, Nijpels G, Stehouwer CD, Pilz S, Brouwer IA. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 2013; 98: E638-E645
• 10 Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, Gaksch M, Grubler M, Fahrleitner-Pammer A, Mrak P, Toplak H, Kraigher-Krainer E, Marz W, Pilz S. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 2014; 63: 20-31
• 11 Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: a clinically relevant research field. Hypertension 2014; 63: 212-214
• 12 Brown JM, Vaidya A. Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes 2014; 21: 193-201
• 13 Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage?. Hypertens Res 2011; 34: 286-288
• 14 Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580
• 15 Zhang C, Miller CL, Brown EM, Yang JJ. The calcium sensing receptor: from calcium sensing to signaling. Sci China Life Sci 2015; 58: 14-27
• 16 Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers S, Conigrave AD, Hampson DR. Calcium-sensing receptor modulates cell adhesion and migration via integrins. J Biol Chem 2011; 286: 40922-40933
• 17 Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71
• 18 Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84: 489-539
• 19 Boulkroun S, Fernandes-Rosa FL, Zennaro MC. Molecular and cellular mechanisms of aldosterone producing adenoma development. Front Endocrinol 2015; 6: 95
• 20 Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572-581
• 21 Silver J, Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol 2010; 25: 2241-2245
• 22 Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239-297
• 23 Brown EM. The extracellular Ca2+-sensing receptor: central mediator of systemic calcium homeostasis. Ann Rev Nutr 2000; 20: 507-533
• 24 Mateus-Hamdan L, Beauchet O, Bouvard B, Legrand E, Fantino B, Annweiler C. High parathyroid hormone, but not low vitamin D concentrations, expose elderly inpatients to hypertension. Geriatr Gerontol Int 2013; 13: 783-791
• 25 Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, Siscovick D, Kestenbaum B. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011; 58: 1021-1028
• 26 Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, Marz W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31: 1591-1598
• 27 Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K, Arnlov J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119: 2765-2771
• 28 Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, A crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther 2013; 27: 161-170
• 29 Monego G, Arena V, Pasquini S, Stigliano E, Fiaccavento R, Leone O, Arpesella G, Potena L, Ranelletti FO, Di Nardo P, Capelli A. Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. Basic Res Cardiol 2009; 104: 427-434
• 30 Yusuf J, Khan MU, Cheema Y, Bhattacharya SK, Weber KT. Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones. Prog Cardiovasc Dis 2012; 55: 77-86
• 31 Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med 2002; 251: 476-483
• 32 Lind L, Ridefelt P, Rastad J, Akerstrom G, Ljunghall S. Relationship between abnormal regulation of cytoplasmic calcium and elevated blood pressure in patients with primary hyperparathyroidism. J Hum Hypertens 1994; 8: 113-118
• 33 Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, Petramala L, Celi M, Minisola S, D’Erasmo E, Mazzuoli GF. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens 2005; 19: 901-906
• 34 Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery 2000; 128: 895-902
• 35 Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003; 27: 216-222
• 36 Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50: 321-328
• 37 Stefenelli T, Abela C, Frank H, Koller-Strametz J, Niederle B. Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery 1997; 121: 157-161
• 38 Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism – an update. Eur J Clin Invest 1998; 28: 271-276
• 39 Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe – nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 (Suppl. 02) N68-N74
• 40 Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the parathyroid epidemiology and audit research study (PEARS). Clin Endocrinol (Oxf) 2011; 75: 169-176
• 41 Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997; 15: 1271-1276
• 42 Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, Corbetti F, Montisci R, Famoso G, Bellu R, Luscher TF, Iliceto S, Tona F. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 2012; 126: 1031-1039
• 43 Brown J, de Boer IH, Robinson-Cohen C, Siscovick DS, Kestenbaum B, Allison M, Vaidya A. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab 2015; 100: 490-499
• 44 Fischer E, Hannemann A, Rettig R, Lieb W, Nauck M, Pallauf A, Bildingmaier M, Beuschlein F, Wallaschofski H, Reincke M. A high aldosterone to Renin ratio is associated with high serum parathyroid hormone concentrations in the general population. J Clin Endocrinol Metab 2014; 99: 965-971
• 45 Tomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H, Kapl M, Grammer T, Ritz E, Horina JH, Kleber ME, Pieske B, Kraigher-Krainer E, Hartaigh BO, Toplak H, van Ballegooijen AJ, Amrein K, Fahrleitner-Pammer A, Marz W. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol 2015; 184: 710-716
• 46 Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, Ayav A, Weryha G, Mirallie E, Bresler L. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 2009; 146: 1035-1041
• 47 Kovacs L, Goth MI, Szabolcs I, Dohan O, Ferencz A, Szilagyi G. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 1998; 138: 543-547
• 48 Pacifici R, Perry 3rd HM, Shieber W, Biglieri E, Droke DM, Avioli LV. Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism. Calcif Tissue Int 1987; 41: 119-123
• 49 Sotornik I, Stribrna J, Hronova J, Kocandrle V, Janata V, Taborsky P, Bultasova H, Zichova M. Changes in plasma renin and aldosterone after parathyroidectomy in patients with hyperparathyroidism. Casopis Lekaru Ceskych 1993; 132: 45-49
• 50 Bernini G, Moretti A, Lonzi S, Bendinelli C, Miccoli P, Salvetti A. Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery. Metabolism 1999; 48: 298-300
• 51 Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski AH. Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 1988; 6: 747-752
• 52 Salahudeen AK, Thomas TH, Sellars L, Tapster S, Keavey P, Farndon JR, Johnston ID, Wilkinson R. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci (Lond) 1989; 76: 289-296
• 53 Rosa J, Raska Jr I, Wichterle D, Petrak O, Strauch B, Somloova Z, Zelinka T, Holaj R, Widimsky Jr J. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res 2011; 34: 296-300
• 54 Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 3326-3330
• 55 Pilz S, Tomaschitz A, Marz W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int 2010; 87: 373-374
• 56 Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, Marz W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 2012; 97: E75-E79
• 57 Tomaschitz A, Fahrleitner-Pammer A, Pieske B, Verheyen N, Amrein K, Ritz E, Kienreich K, Horina JH, Schmidt A, Kraigher-Krainer E, Colantonio C, Meinitzer A, Pilz S. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord 2012; 12: 19
• 58 Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985; 78: 385-390
• 59 Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, De Caro R, Calo LA, Pessina AC, Rossi GP. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens 2012; 30: 390-395
• 60 Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995; 8: 884-893
• 61 Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M, Giacchetti G. Bone health and aldosterone excess. Osteoporos Int 2013; 24: 2801-2807
• 62 Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, Guglielmi G, Desina G, Eller-Vainicher C, Beck-Peccoz P, Scillitani A, Chiodini I. Bone involvement in aldosteronism. J Bone Miner Res 2012; 27: 2217-2222
• 63 Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calo LA, Frigo AC, Fassina A, Pessina AC. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 2012; 60: 431-436
• 64 Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, Reincke M, Quinkler M. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 2014; 99: E1035-E1039
• 65 Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, Vaidya A. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension 2014; 63: 273-280
• 66 Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001; 16: 1496-1504
• 67 Gupta M, Cheung CL, Hsu YH, Demissie S, Cupples LA, Kiel DP, Karasik D. Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res 2011; 26: 1261-1271
• 68 Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 2011; 58: 341-346
• 69 Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 2001; 280: E209-E213
• 70 Olgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab 1994; 20: 309-314
• 71 Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol 1987; 112: 431-437
• 72 Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology 1991; 129: 489-495
• 73 Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab 1992; 75: 988-992
• 74 Fallo F, Rocco S, Pagotto U, Zangari M, Luisetto G, Mantero F. Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. J Hypertension 1989; (Suppl. 07) S192-S193
• 75 Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology 1991; 129: 1233-1242
• 76 Saussine C, Judes C, Massfelder T, Musso MJ, Simeoni U, Hannedouche T, Helwig JJ. Stimulatory action of parathyroid hormone on renin secretion in vitro: a study using isolated rat kidney, isolated rabbit glomeruli and superfused dispersed rat juxtaglomerular cells. Clin Sci (Lond) 1993; 84: 11-19
• 77 Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2: 360-370
• 78 Rafferty B, Zanelli JM, Rosenblatt M, Schulster D. Corticosteroidogenesis and adenosine 3′, 5′- monophosphate production by the amino-terminal (1–34) fragment of human parathyroid hormone in rat adrenocortical cells. Endocrinology 1983; 113: 1036-1042
• 79 Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid “escape” in man. Kidney Int 1972; 2: 279-286
• 80 Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C, Casoli MC, Regolisti G. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens 1998; 11: 8-13
• 81 Kamalov G, Bhattacharya SK, Weber KT. Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol 2010; 56: 320-328
• 82 Abe H, Kubota K, Noie T, Kimura W, Makuuchi M. A rare combination consisting of primary hyperaldosteronism and glucagonoma. Am J Gastroenterol 1999; 94: 1397-1401
• 83 Berbarie RF, Emmett M, Breslau NA. Quiz page. Secondary hypertension with contralateral pheochromocytoma and aldosteronoma. Am J Kidney Dis 2005; 46 A51 e51-e53
• 84 Beckers A, Abs R, Willems PJ, van der Auwera B, Kovacs K, Reznik M, Stevenaert A. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J Clin Endocrinol Metab 1992; 75: 564-570
• 85 Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad Med J 1980; 56: 45-47
• 86 Barkan A, Marilus R, Winkelsberg G, Yeshurun D, Blum I. Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-year-old woman. J Clin Endocrinol Metab 1980; 51: 144-147
• 87 Honda M, Tsukada T, Horiuchi T, Tanaka R, Yamaguchi K, Obara T, Miyakawa H, Yamaji T, Ishibashi M. Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 2004; 43: 310-314
• 88 Chau K, Holmes D, Melck A, Chan-Yan C. Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma. Am J Hypertens 2015; 28: 280-282
• 89 Molina-Ayala M, Ramirez-Renteria C, Manguilar-Leon A, Paul-Gaytan P, Ferreira-Hermosillo A. A rare presentation of primary hyperparathyroidism with concurrent aldosterone-producing adrenal carcinoma. Case Rep Endocrinol 2015; 910984
• 90 Petramala L, Savoriti C, Zinnamosca L, Marinelli C, Settevendemmie A, Calvieri C, Catani M, Letizia C. Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders. Intern Med 2013; 52: 2071-2075
• 91 Concistre A, Petramala L, Zinnamosca L, Settevendemmie A, Corpaci F, Marinelli C, Tonnarini GF, D’Ermo G, De Toma G, Letizia C. Primary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre. Eur Rev Med Pharmacol Sci 2015; 19: 971-976